Free Trial

Codexis, Inc. (CDXS) - What Are Researchers Thinking About This Stock?

Codexis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is mixed: Codexis has an average “Hold” rating from five analysts, with three buy, one hold, and one sell recommendation; the average 12-month price target is $6.
  • Latest quarterly results beat estimates: The company reported a loss of $0.08 per share versus analysts’ expected $0.10 loss, while revenue of $19.26 million also topped estimates.
  • Shares traded at $1.14, within a 52-week range of $0.90 to $2.98. Institutional investors own about 78.5% of the company’s stock.
  • Five stocks to consider instead of Codexis.

Shares of Codexis, Inc. (NASDAQ:CDXS - Get Free Report) have received an average rating of "Hold" from the five analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $6.00.

Several research firms have issued reports on CDXS. Stephens restated an "overweight" rating and set a $5.00 price objective on shares of Codexis in a report on Monday. Wall Street Zen raised shares of Codexis from a "sell" rating to a "hold" rating in a research report on Saturday. Benchmark restated a "hold" rating on shares of Codexis in a report on Thursday, August 20th. Weiss Ratings upgraded shares of Codexis from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 23rd. Finally, Piper Sandler reduced their price target on shares of Codexis from $9.00 to $8.00 and set an "overweight" rating for the company in a research report on Monday, August 17th.

Check Out Our Latest Research Report on Codexis

Institutional Trading of Codexis

A number of hedge funds have recently modified their holdings of CDXS. Bank of New York Mellon Corp raised its stake in shares of Codexis by 2.4% during the 1st quarter. Bank of New York Mellon Corp now owns 209,645 shares of the biotechnology company's stock worth $342,000 after purchasing an additional 4,896 shares in the last quarter. Post Resch Tallon Group Inc. lifted its holdings in shares of Codexis by 1.9% during the 3rd quarter. Post Resch Tallon Group Inc. now owns 573,953 shares of the biotechnology company's stock valued at $798,000 after buying an additional 10,475 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Codexis during the 2nd quarter valued at about $35,000. Corient Private Wealth LP bought a new stake in shares of Codexis in the 2nd quarter valued at approximately $37,000. Finally, Simplicity Wealth LLC bought a new stake in shares of Codexis in the 2nd quarter valued at approximately $39,000. Hedge funds and other institutional investors own 78.54% of the company's stock.

Codexis Price Performance

Shares of CDXS traded down $0.02 during trading hours on Monday, hitting $1.14. 139,915 shares of the company were exchanged, compared to its average volume of 1,387,668. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.06 and a quick ratio of 2.99. The company has a market capitalization of $124.84 million, a PE ratio of -5.70 and a beta of 2.38. The firm has a fifty day simple moving average of $1.29 and a 200-day simple moving average of $1.78. Codexis has a one year low of $0.90 and a one year high of $2.98.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. Codexis had a negative return on equity of 45.54% and a negative net margin of 21.77%. The company had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.72 million. As a group, sell-side analysts predict that Codexis will post -0.37 earnings per share for the current year.

Codexis Company Profile

(Get Free Report)

Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.

Featured Stories

Analyst Recommendations for Codexis (NASDAQ:CDXS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Codexis Right Now?

Before you consider Codexis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Codexis wasn't on the list.

While Codexis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines